In-article:

Alcon: an acquisition in dry eye disease in the USA


(CercleFinance.com) – Alcon announced on Monday that it had reached an agreement to acquire Eysuvis eye drops from the American Kala Pharmaceuticals.

Approved by the FDA in January 2021, this corticosteroid is indicated for the treatment of patients with dry eye, for a period not exceeding two weeks.

The agreement also includes Inveltys, Kala’s ophthalmic solution for the post-operative treatment of patients who have undergone eye surgery.

Alcon points out that Eysuvis generated revenues of $6.3 million last year, while Inveltys had annual sales of $4.9 million.

The Swiss group specifies that it will pay 60 million dollars to complete the operation, an amount to which other payments could be added depending on the achievement of certain commercial milestones.

The transaction should enable it to strengthen its Systane range, a line of eye drops with a lubricating effect, which is already benefiting from the strength of the dry eye market, an application which affects more than 30 million people, just in the USA.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85